RSS
SIGN IN
AI radiology tools are closest to full autonomy, but the FDA's regulatory framework still assumes human-in-the-loop oversight.
True if FDA grants approval for an AI system to make diagnostic decisions without mandatory physician review.
Multiple AI radiology systems outperforming human readers
FDA signaling openness to adaptive frameworks with 500+ cleared devices
Massive cost pressure on healthcare
AI-designed drug zasocitinib in Phase III trials showing FDA acceptance of autonomous AI decisions
173 AI drug programs in clinical development indicating mature regulatory pathways
Analysts predict 60% probability of first approval by 2026-2027
Major pharma investments like Eli Lilly's $2.75B AI deal demonstrate industry confidence
HkeyBio scaling wet-lab validation infrastructure signals AI drug pipeline is maturing toward regulatory submission stages
Liability frameworks don't exist yet for fully autonomous diagnostic tools
AMA lobbying against removal of physician oversight remains active
Current approvals still require human oversight for final decisions
Drug discovery approval pathway differs significantly from diagnostic tool approval — drugs face clinical trials while diagnostics face different regulatory frameworks
Regulatory precedent in drug discovery doesn't automatically translate to autonomous diagnostic tool approval
HkeyBio story actually highlights scale of human validation still required for AI-designed compounds — AI generates candidates but humans still validate, suggesting full autonomy remains distant
5 consecutive upward moves warrant skepticism about whether cumulative evidence justifies +31 point drift from a 25% base